• Explore /
  • Poster
  • / Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma.

Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma.

Abstract Poster

Authors

null

Ke Ji

Beijing Cancer Hospital, Beijing, China;

Ke Ji , Zhaode Bu , Heli Yang , Zhenning Wang , Funan Liu , Pin Liang , Yan Dong , Jie Zhang , Qun Zhao , Yang Liu , Jiafu Ji

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04047953

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 343)

DOI

10.1200/JCO.2023.41.4_suppl.343

Abstract #

343

Poster Bd #

E4

Abstract Disclosures

Similar Posters

First Author: Al Bowen Benson III

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma.

Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma.

First Author: Vikas S. Ostwal

First Author: Davide Melisi

First Author: Qi Lin